Microbiome Therapeutics Market is Expected to Surpass US$ 1801.91 Million by 2032 | Fact.MR

The microbiome therapeutics market is expected to reach $112.20 Million in 2022, growing at a 32% CAGR from 2022 to 2032. The microbiome therapeutics market is expected to reach US$ 1801.91 Million by 2032.

Strategic collaborations for R&D, research and development, and portfolio expansion in the field of microbiome therapies are among the drivers driving market growth. The COVID-19 epidemic had a significant negative influence on the market. Clinical trial research has suffered substantial damage on a global basis. Target diseases are getting more prevalent, which is increasing demand for microbiome therapies.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7844

Key Takeaways

By 2032, it is expected that the application sector for C difficile infection would have the biggest share (33%).
During the projection period, fecal microbiota treatment (FMT) dominated the microbiome therapeutics market.
North America dominated the microbiome therapeutics market, with a 74% share throughout the predicted period.
The United States is expected to account for more than 44% of the global market for microbiome therapies.

Recent Development

Merger

4D Pharma will become a NASDAQ public company in 2020, following its merger with Longevity Acquisition Corporation. According to the agreement, Longevity will assist and advance 4D Pharma's Live Biotherapeutic. The FDA classifies biological products that contain a living organism-such as a bacterium-and are used to treat, prevent, or cure disease as "live biotherapeutics."

Agreement

Nahdi Medical Co. and OptiBiotix Health Plc. inked an exclusive sales and distribution agreement in 2022, which takes effect in 2023. Under a new partnership with Nahdi, the company's GoFigure and SlimBiome Medical weight control solutions will be offered in the Kingdom of Saudi Arabia beginning in early 2022. This will help tackle the obesity pandemic.

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://www.factmr.com/report/microbiome-therapeutics-market

Competitive Landscape

The bulk of microbiome therapies industry participants work with established pharmaceutical corporations and academic institutions. Small start-ups and clinical-stage microbiome companies are using venture money to bring innovative microbiome-based therapies to the worldwide market.

Despite a dip in overall venture capital investments, the microbiome industry received a significant amount of VC funding in 2016, totaling over $336 million. Partnerships and research collaborations are another key trend in the global microbiome therapies industry.

Key Companies Profiled

OpenBiome
Seres Therapeutics Inc.
4D Pharma plc.
Locus Biosciences, Inc.
Enterome SA
Finch Therapeutics Group, Inc.
Intralytix, Inc.
Microbiotica
Second Genome
Rebiotix Inc.
Vedanta Bioscience, Inc.

The United States is expected to hold the highest share, exceeding 44%, of the microbiome therapeutics market. The microbiome therapeutics industry in the United States is predicted to develop as novel drugs are released and used more quickly.

It is projected that Europe would enjoy tremendous growth. Germany is a developing microbiome treatments market in Europe. Even though microbiome therapies are expensive, favorable reimbursement rules are expected to make treatment adoption extremely straightforward in the next years. Additionally, financing is provided to startups for the development and research of microbiome-based products.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7844

Key Segments of Microbiome Therapeutics Industry Research

By Type :
FMT
Microbiome Drugs
By Application :
C. difficile
Crohn's Disease
Inflammatory Bowel Disease
Diabetes

Clostridium difficile infection (CDI or C. difficile) is expected to be the fastest growing application sector in the microbiome therapeutics industry. The rising use of fecal microbiota transplantation (FMT) in Clostridium difficile treatment has contributed to the growth of the microbiome therapeutics market. In repeated occurrences of C difficile, FMT is more effective than antibiotics.

Because of increased attention to microbial changes in Crohn's disease patients, the Crohn's disease application segment is expected to grow profitably during the projected period.

North America dominated the microbiome therapeutics market, garnering the greatest share. The region's popularity is mostly due to its well-established research facilities for developing novel medicines and its growing target population.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.